Anbio Biotechnology Class A Ordinary Shares (NNNN) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Anbio Biotechnology Class A Ordinary Shares (NNNN) trades at a price-to-earnings ratio of 95.6x, with a stock price of $15.30 and trailing twelve-month earnings per share of $0.12.
Compared to the Healthcare sector median P/E of 23.0x, NNNN trades at a 315% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, NNNN commands a significant premium over the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NNNN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NNNN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NNNN P/E vs Peers
Diagnostics and life science tools peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $44B | 42.2 | 2.95Best | +23% | |
| $8B | 10.8Lowest | - | +143%Best | |
| $13B | 31.6 | - | +1% | |
| $17B | 30.5 | - | -25% | |
| $191B | 28.9 | 13.69 | +7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NNNN — Frequently Asked Questions
Quick answers to the most common questions about buying NNNN stock.
What is NNNN's P/E ratio?
Anbio Biotechnology Class A Ordinary Shares (NNNN) trailing twelve-month P/E ratio is 95.6x, based on TTM diluted EPS of $0.12. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is NNNN stock overvalued or undervalued?
NNNN current P/E: 95.6x. 5-year average P/E: N/A. Percentile: N/A.
Is NNNN stock expensive?
NNNN is fairly valued relative to its own history. The current P/E of 95.6x is near the 5-year average of N/A (N/A percentile of historical range).
What is NNNN's historical P/E range?
Over the past 5 years, NNNN's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of 95.6x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does NNNN's P/E compare to the S&P 500?
NNNN trades at 95.6x P/E versus the S&P 500 median of 25.3x. The 278% premium to the market typically reflects higher expected earnings growth or quality.
How does NNNN's valuation compare to Healthcare peers?
Anbio Biotechnology Class A Ordinary Shares P/E of 95.6x compares to the Healthcare sector median of 23.0x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NNNN's PEG ratio?
NNNN PEG ratio is N/A, based on a P/E of 95.6x and EPS growth of 185.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NNNN's earnings yield?
NNNN earnings yield is 1.05%, the inverse of its 95.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.